{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:52:39Z","timestamp":1792511559801,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,26]],"date-time":"2017-02-26T00:00:00Z","timestamp":1488067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["transplantationreviews.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Reviews"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.trre.2017.02.007","type":"journal-article","created":{"date-parts":[[2017,2,28]],"date-time":"2017-02-28T00:32:22Z","timestamp":1488241942000},"page":"151-157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Optimizing everolimus exposure when combined with calcineurin inhibitors in solid organ transplantation"],"prefix":"10.1016","volume":"31","author":[{"given":"Teun","family":"van Gelder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8709-3857","authenticated-orcid":false,"given":"Fuad","family":"Shihab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3790-6634","authenticated-orcid":false,"given":"Maria","family":"Shipkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trre.2017.02.007_bb0005","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2741\/2771","article-title":"Immunosuppression minimization in kidney transplantation","volume":"13","author":"Cantarovich","year":"2008","journal-title":"Front Biosci"},{"key":"10.1016\/j.trre.2017.02.007_bb0010","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nrneph.2010.102","article-title":"Malignancy after renal transplantation: the role of immunosuppression","volume":"6","author":"Rama","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.trre.2017.02.007_bb0015","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/j.1600-6143.2007.01749.x","article-title":"Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus","volume":"7","author":"Vincenti","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.02.007_bb0020","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/tri.12413","article-title":"Cardiovascular morbidity and mortality after kidney transplantation","volume":"28","author":"Stoumpos","year":"2015","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2017.02.007_bb0025","unstructured":"Certican\u00ae (everolimus) Prescribing Information. Novartis Pharma AG, Basel, Switzerland."},{"key":"10.1016\/j.trre.2017.02.007_bb0030","first-page":"199","article-title":"Conversion from tacrolimus to cyclosporin in stable renal transplant patients: safety, metabolic changes, and pharmacokinetic comparison","volume":"70","author":"Higgins","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2017.02.007_bb0035","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1681\/ASN.V1161122","article-title":"Low intraindividual variability of cyclosporin A exposure reduces chronic rejection incidence and health care costs","volume":"11","author":"Kahan","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2017.02.007_bb0040","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/00007890-199609150-00010","article-title":"Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection","volume":"62","author":"Kahan","year":"1996","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2017.02.007_bb0045","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.transproceed.2008.07.029","article-title":"Impact of variability of sirolimus trough level on chronic allograft nephropathy","volume":"40","author":"Wu","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2017.02.007_bb0050","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2125.2009.03392.x","article-title":"Population pharmacokinetics of sirolimus in de novo Chinese adult renal transplant patients","volume":"68","author":"Jiao","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.trre.2017.02.007_bb0055","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1034\/j.1600-6143.2003.00107.x","article-title":"Pharmacokinetics of everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation","volume":"3","author":"Kovarik","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.02.007_bb0060","first-page":"169","article-title":"RADW 102 Renal Transplant Study Group. Pharmacokinetics of the immunosuppressant everolimus in maintenance renal transplant patients","volume":"10","author":"Budde","year":"2005","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.trre.2017.02.007_bb0065","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/00007890-200203270-00016","article-title":"Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range","volume":"73","author":"Kovarik","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2017.02.007_bb0070","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/ctr.12045","article-title":"Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine","volume":"27","author":"Shihab","year":"2013","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2017.02.007_bb0075","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1399-0012.2005.00326.x","article-title":"Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data","volume":"19","author":"Lorber","year":"2005","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2017.02.007_bb0080","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1093\/ndt\/gfh322","article-title":"Et al; RADW 102 Renal Transplant Study Group. Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients","volume":"19","author":"Budde","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2017.02.007_bb0085","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1067\/mcp.2001.112969","article-title":"Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine","volume":"69","author":"Kovarik","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.trre.2017.02.007_bb0090","unstructured":"European medicines agency EMG\/CHMP\/154772\/2016 Committee for Medicinal Products for human use (CHMP) [1 April 2016] http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2016\/05\/WC500205726.pdf"},{"key":"10.1016\/j.trre.2017.02.007_bb0095","author":"Food and Drug Administration"},{"key":"10.1016\/j.trre.2017.02.007_bb0100","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1440-1797.2010.01349.x","article-title":"Review: Pharmacodynamic monitoring of immunosuppression in kidney transplantation","volume":"15","author":"Barraclough","year":"2010","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.trre.2017.02.007_bb0105","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/FTD.0000000000000260","article-title":"Therapeutic drug monitoring of everolimus: a consensus report","volume":"38","author":"Shipkova","year":"2016","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.trre.2017.02.007_bb0110","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.drudis.2015.05.006","article-title":"Sirolimus and everolimus in kidney transplantation","volume":"20","author":"Moes","year":"2015","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.trre.2017.02.007_bb0115","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/01.ftd.0000175911.70172.2e","article-title":"The role of therapeutic monitoring of everolimus in solid organ transplantation","volume":"27","author":"Mabasa","year":"2005","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.trre.2017.02.007_bb0120","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1097\/00007890-200105270-00008","article-title":"RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection","volume":"71","author":"Kahan","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2017.02.007_bb0125","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1097\/01.TP.0000140486.97461.49","article-title":"Haas T; 156 study group. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study","volume":"78","author":"Nashan","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2017.02.007_bb0130","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1097\/01.TP.0000141094.34903.54","article-title":"RAD B201 study group. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients","volume":"78","author":"Vitko","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2017.02.007_bb0135","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1600-6143.2004.00389.x","article-title":"Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies","volume":"4","author":"Vitko","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.02.007_bb0140","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01.TP.0000164352.65613.24","article-title":"Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study","volume":"80","author":"Lorber","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2017.02.007_bb0145","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/00007691-200410000-00007","article-title":"Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation","volume":"26","author":"Kovarik","year":"2004","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.trre.2017.02.007_bb0150","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/TP.0b013e3181de1d67","article-title":"Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients","volume":"90","author":"Chan","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2017.02.007_bb0155","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1432-2277.2012.01465.x","article-title":"Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation","volume":"25","author":"Langer","year":"2012","journal-title":"Transplant Int"},{"key":"10.1016\/j.trre.2017.02.007_bb0160","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1002\/lt.20707","article-title":"Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results","volume":"12","author":"Levy","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2017.02.007_bb0165","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S1053-2498(02)01221-4","article-title":"Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure","volume":"22","author":"Kovarik","year":"2003","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2017.02.007_bb0170","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1600-6143.2010.03129.x","article-title":"Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients","volume":"10","author":"Tedesco-Silva","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.02.007_bb0175","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1097\/TP.0b013e3181bb43ec","article-title":"Everolimus with very low-exposure cyclosporine A in de novo kidney transplantation: a multicenter, randomized, controlled trial","volume":"88","author":"Salvadori","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2017.02.007_bb0180","doi-asserted-by":"crossref","first-page":"613","DOI":"10.5301\/JN.2011.6247","article-title":"Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients","volume":"24","author":"Bertoni","year":"2011","journal-title":"J Nephrol"},{"issue":"Suppl. 6","key":"10.1016\/j.trre.2017.02.007_bb0185","first-page":"353","article-title":"Incidence and risk of infections in renal cell cancer (RCC) and non-RCC patients treated with everolimus and temsirolimus: a meta-analysis of randomized control trials","volume":"31","author":"Je","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trre.2017.02.007_bb0190","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/07357907.2016.1242009","article-title":"Attributable risk of infection to mTOR inhibitors everolimus and temsirolimus in the treatment of cancer","volume":"34","author":"Garcia","year":"2016","journal-title":"Cancer Invest"},{"key":"10.1016\/j.trre.2017.02.007_bb0195","first-page":"2333","article-title":"Risk of anemia attributable to everolimus in patients with cancer: a meta-analysis of randomized controlled trials","volume":"35","author":"Shameem","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.trre.2017.02.007_bb0200","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1185\/03007995.2013.844116","article-title":"Hematologic toxicities associated with mTOR temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis","volume":"30","author":"Xu","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.trre.2017.02.007_bb0205","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1111\/j.1600-6143.2012.04212.x","article-title":"H2304 study group. Everolimus with reduced tacrolimus improved renal function in de novo liver transplant recipients: a randomized controlled trial","volume":"12","author":"De Simone","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.02.007_bb0210","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/ajt.12181","article-title":"Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial","volume":"13","author":"Eisen","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.02.007_bb0215","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1093\/ndt\/gfq096","article-title":"High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation","volume":"25","author":"Borra","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2017.02.007_bb0220","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/ki.2013.465","article-title":"Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure","volume":"85","author":"Sapir-Pichhadze","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2017.02.007_bb0225","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/FTD.0b013e31829a7a7c","article-title":"Racial comparisons of everolimus pharmacokinetics and pharmacodynamics in adult kidney transplant recipients","volume":"35","author":"Taber","year":"2013","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.trre.2017.02.007_bb0230","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1067\/mcp.2001.118022","article-title":"Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications","volume":"70","author":"Kovarik","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.trre.2017.02.007_bb0235","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/11599710-000000000-00000","article-title":"Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients","volume":"51","author":"Moes","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.trre.2017.02.007_bb0240","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.clinthera.2013.02.007","article-title":"Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study","volume":"35","author":"Peveling-Oberhag","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.trre.2017.02.007_bb0245","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00003088-200443020-00002","article-title":"Clinical pharmacokinetics of everolimus","volume":"43","author":"Kirchner","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.trre.2017.02.007_bb0250","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1592\/phco.22.3.154.33542","article-title":"Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants","volume":"22","author":"Kovarik","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.trre.2017.02.007_bb0255","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.pharmthera.2006.04.006","article-title":"An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients","volume":"112","author":"Masuda","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.trre.2017.02.007_bb0260","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1472-8206.2011.00957.x","article-title":"Sirolimus and everolimus intestinal absorption and interaction with calcineurin inhibitors: a differential effect between cyclosporine and tacrolimus","volume":"26","author":"Lamoureux","year":"2012","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.trre.2017.02.007_bb0265","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1016\/j.transproceed.2006.10.092","article-title":"Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus","volume":"38","author":"Kovarik","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2017.02.007_bb0270","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/FTD.0b013e318161a335","article-title":"Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor","volume":"30","author":"Brandhorst","year":"2008","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.trre.2017.02.007_bb0275","doi-asserted-by":"crossref","first-page":"337","DOI":"10.12659\/AOT.890673","article-title":"The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study","volume":"19","author":"Rostaing","year":"2014","journal-title":"Ann Transplant"},{"key":"10.1016\/j.trre.2017.02.007_bb0280","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/ki.2013.484","article-title":"Within-patient variability in immunosuppressive drug exposure as a predictor for poor outcome after transplantation","volume":"85","author":"van Gelder","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2017.02.007_bb0285","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00228-004-0866-5","article-title":"Effect of multiple-dose erythromycin on everolimus pharmacokinetics","volume":"61","author":"Kovarik","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.trre.2017.02.007_bb0290","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1365-2125.2005.02434.x","article-title":"Pharmacokinetic interaction between verapamil and everolimus in healthy subjects","volume":"60","author":"Kovarik","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.trre.2017.02.007_bb0295","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1177\/0091270005275368","article-title":"Blood concentrations of everolimus are markedly increased by ketoconazole","volume":"45","author":"Kovarik","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.trre.2017.02.007_bb0300","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1345\/aph.1A384","article-title":"Effect of rifampin on apparent clearance of everolimus","volume":"36","author":"Kovarik","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.trre.2017.02.007_bb0305","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2165\/00003088-200241110-00003","article-title":"Mechanisms of clinically relevant drug interactions associated with tacrolimus","volume":"41","author":"Christians","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.trre.2017.02.007_bb0310","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1093\/ndt\/gfg381","article-title":"Pharmacokinetic interaction between corticosteroids and tacrolimus and renal transplantation","volume":"18","author":"Anglicheau","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2017.02.007_bb0315","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/0091270002239822","article-title":"Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmocokinetics","volume":"43","author":"Kovarik","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.trre.2017.02.007_bb0320","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1097\/TP.0000000000000782","article-title":"What is the future of generics in transplantation?","volume":"99","author":"van Gelder","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2017.02.007_bb0325","series-title":"QMS\u00ae everolimus immunoassay package insert","author":"Thermo Fisher Scientific Inc.","year":"2015"},{"key":"10.1016\/j.trre.2017.02.007_bb0330","series-title":"Cobas\u00ae everolimus immunoassay package insert (4; revision 1)","author":"Roche Diagnostics GmbH","year":"2016"},{"key":"10.1016\/j.trre.2017.02.007_bb0335","doi-asserted-by":"crossref","DOI":"10.1097\/FTD.0000000000000376","article-title":"Therapeutic drug monitoring of everolimus: comparability of concentrations determined by two immunoassays and a LC-MS\/MS method","author":"Shipkova","year":"2017","journal-title":"Ther Drug Monitor"}],"container-title":["Transplantation Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X16301082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X16301082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T22:15:07Z","timestamp":1658700907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955470X16301082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0955470X16301082"],"URL":"https:\/\/doi.org\/10.1016\/j.trre.2017.02.007","relation":{},"ISSN":["0955-470X"],"issn-type":[{"value":"0955-470X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing everolimus exposure when combined with calcineurin inhibitors in solid organ transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trre.2017.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}